Taysha Gene Therapies stock
TSHANASDAQTaysha Gene Therapies, Inc., HealthcareISIN US8776191061
36Score 36 out of 100, Weak
Price and trend
42 / 100
Price history
0.0% in one yearThe chart shows daily closes over 6 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Below the 200-day line: the price is 19% below it.
Since October 2026 the 50-day line has been below the 200-day line; the trend has turned down.
Normal: the price is neither overheated nor sold off (RSI 58).
The price is 39% below its 52-week high. Largest decline in 6 years: 98% (January 2021 to June 2023).
Chart figures for advanced users
- SMA 50$4.55
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$5.30
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)58
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$3.51
- The lowest closing price of the last twelve months.
- Resistance$6.98
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Taysha Gene Therapies, Inc. belongs to the Biotechnology industry (United States) and, with a market value of $1.58B, is number 153 of 296 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $9.77M (up 17.3% year on year) and a loss of $109M.
- MEQIRI Score 36 out of 100 (Weak): rank 624 of 714 in Healthcare, median 53.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- More cash than debtCash $455.41M, financial debt $55.55M.Stability 53
Weaknesses
- Loss-makingLoss of $149.63M over the last 12 months.Fundamentals 17
- Negative free cash flowFree cash flow −$135.57M over the last 12 months.Fundamentals 17
- Volatile share priceVolatility 72% a year over the last 12 months.Stability 53
The score is held back by capital allocation and fundamentals.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Score since yesterday from 35 to 36.
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansValuation
Valuation signal
not measuredNo fair value can be calculated for this stock, so the signal follows the valuation grade.
Valuation metrics
No fair value can be calculated for this stock from the available figures.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In fiscal 2025, revenue rose 17.3% on the prior year. Revenue has declined since 2023 (-20% per year), so it is worth watching closely. From 2023 revenue is reported differently (for example gross instead of net), so earlier years are not comparable and not shown.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 100%, operating −1131%, net −1115%. Last 12 months: net −100%. From 2023 revenue is reported differently (for example gross instead of net), so earlier years are not comparable and not shown.
Debt & balance sheet
latest quarterDebt is low, but interest coverage is weak. Keep an eye on the interest burden and refinancing.
Earnings
- Next earnings
- 3 Mar 2027in 111 days
- Last reported
- 12 Nov 2026EPS reported −$0.10 (expected −$0.13)above expectations
Analyst estimates
Earnings estimates have barely changed since 15 Oct 2026.
- Earnings per share
- −$0.500.0%
- Revenue
- $1.91M0.0%
- Earnings per share
- −$0.520.0%
- Revenue
- $28.47M0.0%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook confirmed
Share price after the results: +0.6%No guidance change: cash resources are expected to last into the second half of 2028, updates on the pivotal trial expected in the first half of 2027.
“We expect that our current cash resources will support planned operating expenses and capital requirements into the second half of 2028.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 11 Aug 2026 (fiscal Q2 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases in the last 6 months. One insider sold, $1.25M in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
- Nagendran SukumarSale
10 Jul 2026, President and Head of R&D
- Shares
- 200,000
- Price
- $6.24
- Value
- $1.25M
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Taysha Gene Therapies
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 36
- Sector median
- 53
Categories against the sector medianMedian of 714 companies
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Biotechnology
The next larger and next smaller companies by market value
- NanobiotixNANO.PA $1.65B38
- NovavaxNVAX $1.65B45
- Intellia TherapeuticsNTLA $1.6B34
- Immunocore HoldingsIMCR $1.6B47
- Nuvation BioNUVB $1.51B31
- Ocular TherapeutixOCUL $1.46B35
- AnaptysBioANAB $1.46B64
- Alto NeuroscienceANRO $1.45B41
ETFs that hold Taysha Gene Therapies
Held by 11 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| iShares Healthcare Innovation UCITS ETF2B78 | 0.09% | 0.40% | €1.49B |
| iShares Ageing Population UCITS ETF2B77 | 0.09% | 0.40% | €807M |
| iShares Nasdaq US Biotechnology UCITS ETF2B70 | 0.09% | 0.35% | €1.21B |
Show 5 more
| Xtrackers Russell 2000 UCITS ETF 1CXRS2 | 0.04% | 0.30% | €2.17B |
| State Street SPDR Russell 2000 U.S. Small Cap UCITS ETF (Acc)ZPRR | 0.04% | 0.30% | €4.22B |
| State Street SPDR MSCI World Small Cap UCITS ETF (Acc)ZPRS | 0.01% | 0.45% | €1.53B |
| iShares MSCI USA Small Cap CTB Enhanced ESG UCITS ETFSXRG | 0.01% | 0.43% | €2.48B |
| UBS MSCI USA Select Factor Mix UCITS ETF USD accUSUE | 0.00% | 0.25% | €175.89M |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 11 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 30 Sep 2021)
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.